Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1997-06-30
2000-01-18
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
514 2, A61K 39395, A61K 3843, C07K 1628, C07K 1700
Patent
active
060155566
ABSTRACT:
A compound comprises a target cell-specific portion, such as an antibody specific to tumor cell antigens, and an inactivating portion, such as an enzyme, capable of converting a substance which in its native state is able to inhibit the effect of a cytotoxic agent into a substance which has less effect against said cytotoxic agent. The prolonged action of a cytotoxic agent at tumor sites is therefore possible while protecting normal tissues from the effects of the cytotoxic agent.
REFERENCES:
patent: 4624846 (1986-11-01), Goldenberg
Wu, G., et al. , "Model for specific rescue of normal hepatocytes during methotrexate treatment of hepatic malignancy," Proc. Natl. Acad. Sci. USA, 80:3078-80 (1983).
Sauer, H., et al., "Biochemical Control of the Folinic Acid Rescue Effect After High-Dose Methotrexate (MTX) Therapy," Chemistry and Biology of Pteridines. pp. 683-688 (1979).
Riechmann, L., et al., "Reshaping human antibodies for therapy," Nature, 332(6162):323-27 (1988).
Wilkinson, I., et al., "Tolerance Induction in Mice by Conjugates of Monoclonal Immunoglobulins and Monomethoxypolyethylene Glycol," The Journal of Immunology, 139(2):326-31 (1987).
Jodrell, D.I., et al., "The renal effects of N.sup.10 -propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice," Br. J. Cancer, 64:833-38 (1991).
Gilliland, L.K., et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," Proc. Natl. Acad. Sci. USA, 85:7719-23 (1988).
Sharma, S.K., et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model," Br. J. Cancer, 61:659-62 (1990).
Bosslet, K., et al., "Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation," Br. J. Cancer, 65:234-38 (1992).
Morrison, S.L., et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA, 81:6851-55 (1984).
Huber, B.E., et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy," Proc. Natl. Acad. Sci. USA, 88:8039-43 (1991).
Bibby, C., et al., "Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy," Journal of the National Cancer Institute, 81(3):216-20 (1989).
Hennigan, T.W., et al., "Histamine, leukatriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model," Br. J. Cancer, 64:872-74 (1991).
Smyth, M.J., et al., "Increased Antitumor Effect of Immunoconjugates and Tumor Necrosis Factor", Research Center for Cancer and Transplantation, University of Melbourne, Australia.
Harwood, P.J., et al., "Comparative Tumour Localization of Antibody Fragments and Intact IgG in Nude Mice Bearing a CEA-producing Human Colon Tumour Xenograft," Eur J Cancer Clin Oncol, 21(12):1515-22 (1985).
Melton, R.G., et al., "Covalent Linkage of Carboxypeptidase G.sub.2 to Soluble Dextrans-I--Properties of Conjugates and Effects on Plasma Persistence In Mice," Biochemical Pharmacology, 36(1):105-12 (1987).
Melton, R.G., et al., "Covalent Linkage of Carboxypeptidase G.sub.2 to Soluble Dextrans-II--In Vivo Distribution and Fate of Conjugates," Biochemical Pharmacology, 36(1):113-21 (1987).
Antoniw, P., et al., "Disposition of the prodrug-4-(bis(2-chloroethyl)amino) benzoyl-L-glutamic acid and its active parent drug in mice," Br. J. Cancer, 62:909-14 (1990).
Stephens, T.C. Dr., "Development of Anticancer Agents Acting Through Inhibition of Thymidylate Synthase", Bioscience 1, ICI Pharmaceuticals.
Chabner, B.A., et al., "Antitumor Activity of a Folate-cleaving Enzyme, Carboxypeptidase G.sub.1," Cancer Research, 32:2114-19 (1972).
Bagshawe, K.D., "Antibody Directed Enzyme Prodrug Therapy," Analytical Proceedings, 27:5 (1990).
Melton, R.G., et al., "The potential of carboxypeptidase G.sub.2 : antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model," Br. J. Cancer, 61:420-24 (1990).
Senter, P.D., et al., "Anti-tumour effects of antibody-alkaline phosphatase conjugates in combination with etiposide phosphate," Proc. Natl. Acad. Sci. USA, 85:4842-46 (1988).
Bertino, J.R., et al., "Inhibition of Growth of Leukemia Cells by Enzymic Folate Depletion," Science, 172:161-62.
Fernandes, D.J., et al., "5-Fluorouracil-methotrexate synergy: Enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates," Proc. Natl. Acad. Sci. USA, 77(10):5663-67 (1980).
van Groeningen, C.J., et al., "Reversal of 5-Fluorouracil-Induced Myelosuppression by Prolonged Administration of High-Dose Uridine," Journal of the National Cancer Institute. 81(2):157-62 (1989).
Allegra, C.J., et al., "Trimetrexate for the Treatment of Pneumocystis carinii Pneumonia in Patients with the Acquired Immunodeficiency Syndrome," The New England Journal of Medicine, 317(16):978-85 (1987).
Priest, D.G., et al., "Pharmacokinetics of Leucovorin Metabolites on Human Plasma as a Function of Dose Administered Orally and Intravenously," Journal of the National Cancer Institute, 83(24):1806-12 (1991).
Searle, F., et al., "Carboxypeptidase G2 and Trimetrexate Cause Growth Delay of Human Colonic Cancer Cells In Vitro," Biochemical Pharmacology, 39(11):1787-91 (1990).
Kanellos, J., et al., "Studies of Methotrexate-Monoclonal Antibody Conjugates for Immunotherapy," JNCI, 75(2):319-29 (1985).
Morell, A.G., et al., "The Role of Sialic Acid in Determining the Survival of Glycoproteins in the Circulation," The Journal of Biological Chemistry, 246(5):1461-67 (1971).
Begent, R.H.J., "Targeted therapy: cell surface targets," Science of Cancer Treatment, pp. 161-184.
Begent, R.H.J., et al., "Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies," Clin. exp. Immunol., 78:307-13 (1989).
Thornburg, R.W., et al., "Carbohydrate-mediated Clearance of Immune Complexes from the Circulation," The Journal of Biological Chemistry, 255(14):6820-25 (1980).
Haenseler, E., et al., "Activation of Methotrexate-.alpha.-Alanine by Carboxypeptidase A-Monoclonal Antibody Conjugate," Biochemistry, 31(3):891-97 (1992).
Barbet et al., "Specific Toxicity to activated T and B Lymphocytes of a Ricin A Immunotoxin Directed Against the Class I MHC Antigen, H-2 K," Antibody, Immunoconjugates, Radiopharm, 1(2):169-80 (1988).
Bagshawe, K.D., et al., Br. J. Cancer, 58:700-03 (1988).
Bansal Geetha P.
Enzacta R & D Limited
Hutzell Paula K.
LandOfFree
Cytotoxic drug therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic drug therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic drug therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-561152